United States Biotechnology & Medical Research

Neurogene Inc (NGNE)

Track

Over the past 90 days, Neurogene Inc. has seen significant insider selling activity, totaling approximately $1.06 million in sales. These transactions were primarily executed by President and CFO Christine Cvijic through planned sales. This activity follows the company's May 2026 earnings report, which showed an EPS miss of 9.05%.
Ticker: NGNE Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Neurogene Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 7 Jul 2026
Value US$1,028,425.44 | Price 141.85 | Shares 4,042 (+48.3%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-07 2026-07-07 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
4,042 +48.3%
141.85
US$1,028,425 		4,042 +48.3% 141.85 US$1,028,425
2026-07-07 2026-07-06 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
66,771 -20.1%
486.23
US$2,468,523 		66,771 -20.1% 486.23 US$2,468,523
2026-07-02 2026-07-02 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
82,678 -3.3%
69.78
US$4,469,267 		82,678 -3.3% 69.78 US$4,469,267
2026-07-02 2026-07-02 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
2,531 -2.7%
34.58
US$87,519 		2,531 -2.7% 34.58 US$87,519
2026-07-02 2026-07-01 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
739 -0.8%
34.06
US$25,170 		739 -0.8% 34.06 US$25,170
2026-05-08 2026-05-06 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
4,800 -4.9%
32.44
US$155,692 		4,800 -4.9% 32.44 US$155,692
2026-05-08 2026-05-06 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Executive Director
4,800 -4.6%
30.07
US$144,351 		4,800 -4.6% 30.07 US$144,351
2026-05-06 2026-05-06 PrS Proposed sale
2.3
Christine Cvijic

Officer

Officer
14,400
28.94
US$416,736 		14,400 28.94 US$416,736
2026-03-30 2026-03-26 S Sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
2,558 -2.4%
21.62
US$55,316 		2,558 -2.4% 21.62 US$55,316
2026-03-30 2026-03-26 S Sale
2.0
McMinn Rachel

Chief Executive Officer

Executive Director
3,352 -0.2%
22.07
US$73,995 		3,352 -0.2% 22.07 US$73,995
2026-03-30 2026-03-26 S Sale
1.4
Jordan Julie

Chief Medical Officer

Officer
828 -6.2%
21.89
US$18,128 		828 -6.2% 21.89 US$18,128
2026-03-17 2026-03-13 PlS Planned sale
Cobb Stuart

Chief Scientific Officer

Officer
148 -0.5%
22.08
US$3,268 		148 -0.5% 22.08 US$3,268
2026-03-17 2026-03-13 PlS Planned sale
Cobb Stuart

Chief Scientific Officer

Officer
2,658 -8.0%
21.34
US$56,722 		2,658 -8.0% 21.34 US$56,722
2026-03-17 2026-03-13 PlS Planned sale
Cobb Stuart

Chief Scientific Officer

Officer
3,991 -10.7%
20.41
US$81,456 		3,991 -10.7% 20.41 US$81,456
2026-03-17 2026-03-13 S Sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
263 -0.2%
22.02
US$5,791 		263 -0.2% 22.02 US$5,791
2026-03-17 2026-03-13 S Sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
1,395 -1.3%
21.25
US$29,637 		1,395 -1.3% 21.25 US$29,637
2026-03-17 2026-03-13 S Sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
2,387 -2.2%
20.42
US$48,748 		2,387 -2.2% 20.42 US$48,748
2026-03-13 2026-03-13 PrS Proposed sale
STUART COBB

Officer

Officer
6,797
22.30
US$151,573 		6,797 22.30 US$151,573
2026-03-03 2026-02-27 PlS Planned sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
4,800 -4.2%
25.11
US$120,526 		4,800 -4.2% 25.11 US$120,526
2026-02-27 2026-02-27 PrS Proposed sale
2.3
Christine Cvijic

Officer

Officer
9,600
19.68
US$188,928 		9,600 19.68 US$188,928
2025-05-15 2025-05-14 PlS Planned sale
Cobb Stuart

Chief Scientific Officer

Officer
6,797 -24.6%
15.15
US$103,003 		6,797 -24.6% 15.15 US$103,003
2025-05-14 2025-05-14 PrS Proposed sale
STUART COBB

Officer

Officer
6,797
15.51
US$105,421 		6,797 15.51 US$105,421
2025-03-17 2025-03-13 S Sale
2.3
Cvijic Christine Mikail

President and CFO

Officer
4,501 -5.9%
16.94
US$76,247 		4,501 -5.9% 16.94 US$76,247
2024-11-27 2024-11-26 B Purchase
3.6
Samsara BioCapital GP, LLC
Large shareholder
2,000 +0.1%
27.50
US$55,000 		2,000 +0.1% 27.50 US$55,000
2024-11-27 2024-11-26 B Purchase
3.6
Samsara BioCapital GP, LLC
Large shareholder
15,219 +0.9%
26.73
US$406,804 		15,219 +0.9% 26.73 US$406,804
2024-11-27 2024-11-26 B Purchase
3.6
Samsara BioCapital GP, LLC
Large shareholder
10,803 +0.6%
26.01
US$280,986 		10,803 +0.6% 26.01 US$280,986
2024-11-27 2024-11-26 B Purchase
3.6
Samsara BioCapital GP, LLC
Large shareholder
20,748 +1.2%
24.91
US$516,833 		20,748 +1.2% 24.91 US$516,833
2024-11-25 2024-11-22 B Purchase
2.0
McMinn Rachel

Chief Executive Officer

Executive Director
47,500 +3.8%
20.40
US$969,000 		47,500 +3.8% 20.40 US$969,000
2024-11-25 2024-11-22 B Purchase
2.3
Cvijic Christine Mikail

President and CFO

Officer
24,000 +45.4%
20.48
US$491,400 		24,000 +45.4% 20.48 US$491,400
2024-03-07 2024-03-07 PrS Proposed sale
0.5
MARTIN BABLER

Director

Non-Executive Director
2,500
39.29
US$98,234 		2,500 39.29 US$98,234
2024-03-04 2024-03-04 PrS Proposed sale
2.4
SEAN SMITH

Officer

Officer
371
36.57
US$13,567 		371 36.57 US$13,567
2024-02-09 2024-02-09 PrS Proposed sale
2.1
TODD SIMPSON

Director

Non-Executive Director
2,500
31.00
US$77,500 		2,500 31.00 US$77,500
2024-02-06 2024-02-06 PrS Proposed sale
ERIN LAVELLE

Director

Non-Executive Director
2,500
30.45
US$76,125 		2,500 30.45 US$76,125
2023-08-17 2023-08-17 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
61,134 +1.1%
0.69
US$42,354 		61,134 +1.1% 0.69 US$42,354
2023-08-17 2023-08-17 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
5,041 +1.0%
0.69
US$3,492 		5,041 +1.0% 0.69 US$3,492
2023-08-17 2023-08-17 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
93,091 +1.7%
0.69
US$64,456 		93,091 +1.7% 0.69 US$64,456
2023-08-17 2023-08-17 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
7,676 +1.6%
0.69
US$5,315 		7,676 +1.6% 0.69 US$5,315
2023-08-17 2023-08-16 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
4,434 +0.1%
0.68
US$3,028 		4,434 +0.1% 0.68 US$3,028
2023-08-17 2023-08-16 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
366 +0.1%
0.68
US$250 		366 +0.1% 0.68 US$250
2023-08-17 2023-08-16 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
207,676 +4.0%
0.68
US$141,324 		207,676 +4.0% 0.68 US$141,324
2023-08-17 2023-08-16 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
17,124 +3.7%
0.68
US$11,653 		17,124 +3.7% 0.68 US$11,653
2023-08-17 2023-08-15 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
4,342 +0.1%
0.67
US$2,887 		4,342 +0.1% 0.67 US$2,887
2023-08-17 2023-08-15 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
358 +0.1%
0.67
US$238 		358 +0.1% 0.67 US$238
2023-08-17 2023-08-15 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
1,740,581 +49.7%
0.63
US$1,097,958 		1,740,581 +49.7% 0.63 US$1,097,958
2023-08-17 2023-08-15 B Purchase
3.3
BAKER BROS. ADVISORS LP
Non-Executive Director Large shareholder
143,519 +44.8%
0.63
US$90,532 		143,519 +44.8% 0.63 US$90,532
2023-08-14 2023-08-11 PlS Planned sale
2.4
Smith Sean Michael

Interim CFO, Prin Acct Off

Officer
1,323 -5.8%
0.62
US$818 		1,323 -5.8% 0.62 US$818
2023-04-04 2023-04-03 S Sale
1.3
Patel Priti

Former Chief Medical Officer
3,769 -9.2%
0.69
US$2,608 		3,769 -9.2% 0.69 US$2,608
2023-02-03 2023-02-02 S Sale
2.4
Smith Sean Michael

Principal Accounting Officer

Officer
3,316 -17.2%
0.60
US$1,980 		3,316 -17.2% 0.60 US$1,980
2023-02-03 2023-02-02 PlS Planned sale
1.3
Patel Priti

Chief Medical Officer

Officer
14,380 -31.6%
0.60
US$8,588 		14,380 -31.6% 0.60 US$8,588
2022-08-12 2022-08-10 S Sale
2.4
Smith Sean Michael

Principal Accounting Officer

Officer
1,655 -19.6%
0.99
US$1,641 		1,655 -19.6% 0.99 US$1,641
2022-05-03 2022-05-02 PlS Planned sale
1.3
Patel Priti

Chief Medical Officer

Officer
5,538 -46.2%
1.22
US$6,749 		5,538 -46.2% 1.22 US$6,749
2021-06-17 2021-06-16 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
10.19
US$6,114 		600 -0.0% 10.19 US$6,114
2021-06-11 2021-06-09 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
650 -0.0%
10.82
US$7,036 		650 -0.0% 10.82 US$7,036
2021-06-09 2021-06-08 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
11.00
US$6,600 		600 -0.0% 11.00 US$6,600
2021-06-07 2021-06-04 B Purchase
2.8
DRACHMAN JONATHAN G

President and CEO

Executive Director
10,000 +0.4%
9.61
US$96,082 		10,000 +0.4% 9.61 US$96,082
2021-06-07 2021-06-03 B Purchase
2.8
DRACHMAN JONATHAN G

President and CEO

Executive Director
40,000 +1.8%
9.48
US$379,272 		40,000 +1.8% 9.48 US$379,272
2021-05-26 2021-05-26 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
10.00
US$6,000 		600 -0.0% 10.00 US$6,000
2021-05-21 2021-05-19 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
10.63
US$6,378 		600 -0.0% 10.63 US$6,378
2021-05-12 2021-05-12 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,200 -0.1%
11.09
US$13,308 		1,200 -0.1% 11.09 US$13,308
2021-05-06 2021-05-05 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,200 -0.1%
11.30
US$13,560 		1,200 -0.1% 11.30 US$13,560
2021-04-30 2021-04-28 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
2,400 -0.2%
12.58
US$30,192 		2,400 -0.2% 12.58 US$30,192
2021-04-27 2021-04-26 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
13.00
US$7,800 		600 -0.0% 13.00 US$7,800
2021-04-22 2021-04-21 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
11.98
US$21,564 		1,800 -0.1% 11.98 US$21,564
2021-04-16 2021-04-14 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
12.22
US$21,996 		1,800 -0.1% 12.22 US$21,996
2021-04-08 2021-04-07 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
12.02
US$21,636 		1,800 -0.1% 12.02 US$21,636
2021-04-06 2021-04-05 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
13.00
US$7,800 		600 -0.0% 13.00 US$7,800
2021-04-02 2021-03-31 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
11.96
US$21,528 		1,800 -0.1% 11.96 US$21,528
2021-03-24 2021-03-24 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
11.95
US$21,516 		1,800 -0.1% 11.95 US$21,516
2021-03-24 2021-03-22 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
12.00
US$7,200 		600 -0.0% 12.00 US$7,200
2021-03-18 2021-03-17 S Sale
2.2
Ho Robert

Chief Financial Officer

Officer
6,497 -23.2%
11.01
US$71,556 		6,497 -23.2% 11.01 US$71,556
2021-03-18 2021-03-17 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,200 -0.1%
11.36
US$13,632 		1,200 -0.1% 11.36 US$13,632
2021-03-11 2021-03-10 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
11.97
US$21,540 		1,800 -0.1% 11.97 US$21,540
2021-03-04 2021-03-03 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
11.87
US$21,360 		1,800 -0.1% 11.87 US$21,360
2021-02-25 2021-02-25 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
600 -0.0%
13.00
US$7,800 		600 -0.0% 13.00 US$7,800
2021-02-25 2021-02-24 PlS Planned sale
Walkey Carl

Senior Vice President

Officer
1,800 -0.1%
12.14
US$21,852 		1,800 -0.1% 12.14 US$21,852
Explore more

More insider trading research around Neurogene Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America